康缘药业(600557) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,078,624,792.24, representing a year-on-year increase of 25.16%[5] - The net profit attributable to shareholders of the listed company was CNY 109,985,159.38, up 30.94% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 106,630,369.84, reflecting a 34.69% increase year-on-year[5] - The basic earnings per share for the period was CNY 0.19, an increase of 26.67% compared to the previous year[5] - Total operating revenue for Q1 2022 reached CNY 1,078,624,792.24, a 25.2% increase from CNY 861,784,479.53 in Q1 2021[25] - Net profit for Q1 2022 was CNY 110,378,236.08, representing a 29.2% increase compared to CNY 85,495,310.26 in Q1 2021[26] - Earnings per share for Q1 2022 were CNY 0.19, up from CNY 0.15 in Q1 2021[28] - The company reported a comprehensive income attributable to shareholders of the parent company of CNY 109,985,159.38 in Q1 2022, compared to CNY 83,997,468.15 in Q1 2021[28] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 5,984,972,937.48, a decrease of 0.55% from the end of the previous year[7] - The company's total assets were CNY 5,984,972,937.48 in Q1 2022, slightly down from CNY 6,018,019,235.83 in Q1 2021[25] - The company's cash and cash equivalents decreased to approximately RMB 721.91 million from RMB 937.44 million year-over-year, reflecting a decline of about 23%[20] - The company's total liabilities decreased to approximately RMB 1.31 billion from RMB 1.45 billion, reflecting a decline of about 9.8%[22] - Total liabilities decreased to CNY 1,401,874,399.94 in Q1 2022 from CNY 1,545,298,934.37 in Q1 2021[25] - The company's non-current assets totaled approximately RMB 3.13 billion, down from RMB 3.14 billion, indicating a decrease of about 0.5%[22] - The company’s short-term borrowings decreased significantly to RMB 110 million from RMB 234.5 million, a reduction of approximately 53%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,836[11] - The total number of shares held by the top ten unrestricted shareholders is 176,173,467 shares by Jiangsu Kangyuan Group Co., Ltd., accounting for a significant portion of the company's equity[14] - The company plans to cancel 16,452,086 repurchased shares to reduce registered capital, which was approved in the board meeting on January 12, 2022[16] Research and Development - Research and development expenses for the period amounted to CNY 144,196,379.61, a 39.18% increase from CNY 103,601,243.98 in the same period last year[10] - Research and development expenses for Q1 2022 amounted to CNY 144,196,379.61, an increase from CNY 103,601,243.98 in Q1 2021[25] Cash Flow Management - The company reported a net cash flow from operating activities of CNY 79,139,904.88, with no year-on-year comparison available[5] - In Q1 2022, Jiangsu Kangyuan Pharmaceutical Co., Ltd. reported cash inflows from operating activities of approximately CNY 1.12 billion, a 30% increase from CNY 857.75 million in Q1 2021[30] - The net cash flow from operating activities was CNY 79.14 million, compared to a negative CNY 26.92 million in the same period last year, indicating a significant turnaround[30] - Cash outflows for purchasing goods and services increased to CNY 280.10 million from CNY 134.56 million, reflecting a 108% rise year-over-year[30] - Investment activities generated a net cash outflow of approximately CNY 168.37 million, worsening from a net outflow of CNY 98.57 million in Q1 2021[31] - Cash and cash equivalents at the end of Q1 2022 stood at CNY 721.91 million, up from CNY 434.01 million at the end of Q1 2021, marking a 66% increase[31] - The company reported cash inflows from investment activities totaling CNY 282.13 million, down from CNY 406.67 million in the previous year[31] - Total cash outflows from financing activities decreased to CNY 126.30 million from CNY 400.31 million, indicating a reduction in financing costs[31] - The company did not receive any cash from new investments or borrowings in Q1 2022, compared to CNY 191 million in Q1 2021[31] - The net increase in cash and cash equivalents for the quarter was a decrease of CNY 215.53 million, an improvement from a decrease of CNY 334.81 million in the same quarter last year[31] - Jiangsu Kangyuan Pharmaceutical's cash flow management reflects a strategic focus on improving operational efficiency and reducing financing dependency[30] Market Position - The company’s unique product, "Re Du Ning Injection," was included in the national treatment plan for severe COVID-19 cases, enhancing its market position[18]